Metronomic oral cyclosphosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma

Lee, Victor; Kwong, Dora Lai-Wan; Lam, Ka-On; Lai, Yu-Ching; Li, Yun; Tong, Chi-Chung; Ho, P.; Chan, Wing‐Lok; Wong, Lai‐San; Leung, Dennis K.C.; Chan, Sum‐Yin; Chan, Fong-Ting; Leung, TW; Lee, Anne W.M.

doi:10.1097/md.0000000000006518

Cited by 8 publications

(9 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three studies reported median PFS [21][22][23]. The matched pair analysis [24] showed a bene t for cetuximab-based chemotherapy in terms of superior median PFS and OS.…”

Section: Primary and Secondary Outcomesmentioning

confidence: 99%

“…Then 67 records including 9 comments or abstracts related to the aim of study were excluded. Finally, 13 records meeting criteria, including 3 randomized control trails [17][18][19], 1 cohort study [20], 4 prospective studied (3 single arm trials [21][22][23], 1 match pair analysis [24]) and 5 retrospective studies [25][26][27][28][29] were included.…”

Section: Study Selectionmentioning

confidence: 99%

“…Four studies reported their dropout or loss data [17,19,21,23], while remaining did not give the information. Of all the studies included, nine were conducted in India [17,19,21,[23][24][25][27][28][29], and two in the USA[18, 26], two in China (Taiwan [20] and Hong Kong [22]).…”

Section: Study Characteristicmentioning

confidence: 99%

“…The cohort study [20] only gave outcome of survival rate (SR) of two groups. Three prospective studies reported Median OS [21,22,24]. One study did not calculate median OS for less deaths at median follow-up [23].…”

Section: Primary and Secondary Outcomesmentioning

confidence: 99%

See 3 more Smart Citations

The Effectiveness and Safety of Metronomic Chemotherapy in Patients with Head and Neck Carcinoma: A Systematic Review and Meta-analysis

Wang

Zhang

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Head and neck carcinoma, usually begins in the squamous cells, not only seriously endangers the quality of life, but brings a heavy financial burden for families and countries. Metronomic chemotherapy, a frequent administration of chemotherapeutic agents at a non-toxic dose, gives an alternative low-cost and tolerated approach for patients. We conducted a systematic review to find the effectiveness and safety of metronomic chemotherapy for head and neck cancer.Methods: We searched seven databases and Clinical.gov from the inception to July 14, 2021. The patients diagnosed head and neck cancer and older than 18 were included. Metronomic chemotherapy was defined as intervention. Randomized and non-randomized trials were all included. Quality assessment of included randomized control trials was performed using the Cochrane Risk-of-Bias criteria, cohort studies using The Newcastle-Ottawa Scale (NOS), single arm trials using the checklist recommended by The Agency for Healthcare Research and Quality (AHRQ). Studies were synthetized using a narrative approach. The indicators used for meta-analysis was hazard ratio (HR).Results: 310 Literatures were potentially eligible from 7 databases, finally 13 records were included. Five studies were of high quality, while eight were of moderate quality. The overall effect of HR for death of five trials reported had no statistically significant (HR=0.89, 95%CI 0.71-1.10). Subgroup analysis by different design showed a statistically significant HR (0.73, 95%CI 0.60-0.90) in randomized control trials while no significant difference in subgroup of prospective study design (HR=1.23, 95%CI 0.72-2.10). As for HR for PFS, there was no significant difference in overall effect of four studies. HR for PFS was 0.84 (95%CI 0.55-1.31). Subgroup analysis of study design showed that randomized control trials produced a significant HR (0.54, 95%CI 0.45-0.64), while prospective studies did not (1.25, 95%CI 0.73, 2.14).Conclusions: Metronomic chemotherapy has been an optimistic option for treatment for advanced head and neck cancer, especially in low income and medical resource-restricted regions.

show abstract

“…Three studies reported median PFS [21][22][23]. The matched pair analysis [24] showed a bene t for cetuximab-based chemotherapy in terms of superior median PFS and OS.…”

Section: Primary and Secondary Outcomesmentioning

confidence: 99%

Section: Study Selectionmentioning

confidence: 99%

Section: Study Characteristicmentioning

confidence: 99%

Section: Primary and Secondary Outcomesmentioning

confidence: 99%

See 2 more Smart Citations

The Effectiveness and Safety of Metronomic Chemotherapy in Patients with Head and Neck Carcinoma: A Systematic Review and Meta-analysis

Wang

Zhang

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Nevertheless, the evidence of chemotherapy as subsequent systemic therapy following failure to 1 st line chemotherapy is less well-defined. Single agent without platinum, e.g., gemcitabine, taxane, capecitabine and metronomic cyclophosphamide, is an also acceptable option for heavily pretreated patients (8)(9)(10)(11). Targeted therapy including anti-EGFR (gefitinib and cetuximab), anti-VEGF/VEGFR (axitinib), multi-kinase tyrosine kinase inhibitor (sorafenib and sunitinib) and Akt inhibitor were also evaluated in numerous phase II trials (12)(13)(14)(15).…”

mentioning

confidence: 99%